Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.

This resolution states the opinion of the U.S. House of Representatives on the abortion medication mifepristone. It says FDA policies on access to medication abortion must be based on a transparent scientific review of medical evidence and on the burdens rules place on patients and the health care system. It states that the FDA has reviewed mifepristone several times over 25 years and found it safe and effective, including when prescribed by telemedicine and sent by mail or filled at a pharmacy. It also states that keeping and expanding access to medication abortion, including by telemedicine and mail, is important for equal access to abortion. The resolution does not change any law.

Full text and official record on Congress.gov

Sponsors

• Diana DeGette Democrat sponsor
• 54 cosponsors